Mark‐Alexander Schwarzbich

The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors

Mark‐Alexander Schwarzbich, Michael Gutknecht, Julia Salih et al. · Cancer Immunology Immunotherapy · 2011 · 39 citations · Full text

Inflammation, Immune Cell Development, Medicine +14

The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma

Michael Madle, Isabelle Krämer, Nicola Lehners et al. · Annals of Hematology · 2015 · 25 citations

Neuro-oncology, Lymphoid Neoplasia, Cell Therapy +8

CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease

Nicola Giesen, Mark‐Alexander Schwarzbich, Katharina Dischinger et al. · Transplantation · 2020 · 22 citations

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Katharina Lisenko, Fabienne McClanahan, Tilman Schöning et al. · BMC Cancer · 2016 · 12 citations · Full text

Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era

Nicola Lehners, Isabelle Krämer, Mark‐Alexander Schwarzbich et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 10 citations

Neuro-oncology, Lymphoid Neoplasia, Urology +11